Cell wall-deficient bacteria as a cause of infections: A review of the clinical significance

Journal of International Medical Research

Volumn 33, Issue 1, 2005, Pages 1-20

  Onwuamaegbu, M E ^a   Belcher, R A ^b   Soare, C ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

^c UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

Author keywords

Atypical bacteria; Cell wall deficient bacteria; Clinical significance; L form; Wild type bacteria

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ATORVASTATIN; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; GATIFLOXACIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MACROLIDE; METICILLIN; METRONIDAZOLE; OMEPRAZOLE; OXACILLIN; PLACEBO; PRAVASTATIN; PROBIOTIC AGENT; RIFABUTIN; ROXITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBODY TITER; ARTHRITIS; BACTERIAL CELL WALL; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BLOOD CULTURE; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROHN DISEASE; DISEASE ASSOCIATION; DRUG RESPONSE; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; INTESTINE LIPODYSTROPHY; NONHUMAN; OSTEOMYELITIS; REVIEW; RHEUMATIC FEVER; RISK REDUCTION; SARCOIDOSIS; SPECIES IDENTIFICATION; URINALYSIS; URINARY TRACT INFECTION; UVEITIS;

EID: 13444304483     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000503300101     Document Type: Review

References (143)

1. Domingue GJ, Woody HB: Bacterial persistence and expression of disease. Clin Microbiol Rev 1997; 10: 320-344.
2. Mattman LH: Stealth Pathogens, 3rd edn. Boca Raton, London, New York, Washington DC: CRC Press, 2001.
3. Kagan YG: Some aspects of investigations of the pathogenic potentialities of L-forms of bacteria. In: Microbial Protoplasts, Spheroplasts and L-forms (Guze LB, ed). Baltimore: Williams & Wilkins Co., 1968; pp422-443.
4. Dienes L: The development of Proteus cultures in the presence of penicillin. J Bacteriol 1949; 57: 529-546.
5. Tulasne R, Vendrely R: Cytology of Staphylococci before and after treatment with penicillin. Nature 1948; 316-317.
6. Charache P: Cell wall-defective bacterial variants in human disease. Ann N Y Acad Sci 1970; 174: 903-911.
7. Klieneberger-Nobel E: Filterable forms of bacteria. Bacteriol Rev 1951; 15: 77-103.
8. Klieneberger E: The natural occurrence at pleuro-pneumonia-like organisms in apparent symbiosis with Streptobacillus moniliformis and other bacteria. J Path Bact 1935; 40: 93-97.
9. Woo PC, Wong SS, Lum PN, Hui WT, Yuen KY: Authors' reply. Lancet 2001; 357: 1886.
10. Pfeiffer R: Differential Diagnose der vibrionen de cholera asiatica mit hulfe der immunieserung. Z Hyg Infekt Kr 1895; 19: 75-77.
11. Barile MF: Variant bacteria and chronic disease. Hosp Pract 1968; 3: 41-45.
12. Medill MA, O'Kane DJ: Synthetic medium for L-type colonies of Proteus. J Bacteriol 1954; 68: 530-533.
13. Mattman L, Tunstall L, Mathews W, Gordon DL: L-variation in mycobacteria. Am Rev Respiratory Dis 1960; 82: 202-211.
14. Butler HM, Blakey JL: A review of bacteria in L-phase and their possible clinical significance. Med J Aust 1975; 2: 463-467.
15. Schmitt-Slomska J, Roux J: Cell wall-defective organisms as a model for the study of antibiotic activity. In: Spheroplasts, Protoplasts and L-forms of Bacteria (Roux J, ed). Paris: INSERM, 1977; pp185-196.
16. Wieckiewicz J: Loss of virulence of revertants from Staphylococcus aureus L-phase variants in comparison with the parent strain. J Hyg Epidemiol Microbiol Immunol 1979; 23: 326-331.
17. Bisset KA, Bartlett R: The isolation and characters of L-forms and reversions of Bacillus licheniformis var endoparasiticus (Benedek) associated with the erythrocytes of clinically normal persons. J Med Microbiol 1978; 11: 335-349.
18. Domingue GJ: Filterable, cell-associated cell wall-deficient bacteria in renal diseases. In: Cell Wall-deficient Bacteria: Basic Principles and Clinical Significance (Domingue GJ, ed).Reading, MA: Addison-Wesley Publishing Co., 1982; pp121.
19. Theodore TS, Tully IG, Cole RM: Polyacrylamide gel identification of bacterial L forms and mycoplasma species of human origin. Appl Microbiol 1971; 21: 272-277.
20. Markesich DC, Graham DY, Yoshimuru HH: Progress in culture and subculture of spheroplasts and fastidious acid-fast bacilli isolated from intestinal tissues. J Clin Microbiol 1988; 26: 1600-1603.
21. Moss MT, Sanderson JD, Tizard ML, Hermon-Taylor J, El-Zaatari FA, Markesich DC, et al: Polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp silvaticum in long term cultures from Crohn's disease and control tissues. Gut 1992; 33: 1209-1213.
22. Edman DC, Pollock MB, Hall ER: Listeria monocytogenes L forms. I. Induction, maintenance, and biological characteristics. J Bacteriol 1968; 96: 352-357.
23. Naser SA, Hulten K, Shafron I, Graham DY, El-Zaatari FA: Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet Microbiol 2000; 77: 497-504.
24. Hulten K, Karttunen TJ, El-Zimaity HM, Naser SA, Almashhrawi A, Graham DY, et al: In situ hybridization method for studies of cell wall deficient M. paratuberculosis in tissue samples. Vet Microbiol 2000; 77: 513-518.
25. Moss MT, Green EP, Tizard ML, Malik ZP, Herman-Taylor J: Specific detection of Mycobacterium paratuberculosis by DNA hybridisation with a fragment of the insertion element IS900. Gut 1991; 32: 395-398.
26. Orskov J: Some observations on aberrant bacterial morphology: Proteus vulgaris. Acta Pathol Microbiol Scand 1947; 24: 198-202.
27. Dienes L: Further observations on the reproduction of bacilli from large bodies in Proteus cultures. Proc Soc Exp Biol Med 1947; 66: 97-98.
28. Schellenberg H: [Studies on penicillin-induced pleomorphia in Proteus vulgaris.] Zentralbl Bakteriol/Orig/ 1954; 161: 433-457 (in German).
29. Nelles A: [Multiplications of stable L-forms of bacteria.] Arch Hyg Bakteriol 1955; 139: 294-304 (in German).
30. Hahn RE, Ciak J: Penicillin-induced lysis of E. coli. Science 1957; 125: 119-120.
31. Klieneberger-Nobel E: The L-cycle: a process of regeneration in bacteria. J Gen Microbiol 1951; 5: 525-530.
32. Dienes L: Further observations on the reproduction of bacilli from large bodies in Proteus cultures. Proc Soc Exp Biol Med 1947; 66: 97-98.
33. Madoff S: The Bacterial L-forms. New York: Marcel Dekker Inc., 1986.
34. Gurfinkel E: Inflammation, infection, or both in atherosclerosis: the ROXIS trial in perspective. J Infect Dis 2000; 181 (Suppl 3): S566-S568.
35. Schmitt-Slomska J, Drach G, Caravano R: Incidence of cellular and humoral factors on group A streptococcal L forms. 1. Microscopic study of the association of L-forms with human polymorphonuclear leukocytes and mouse peritoneal macrophages. Ann Microbiol (Paris) 1973; 124: 329-350.
36. Panos C, Barkulis SS, Hayashi JA: Streptococcal L forms. II. Chemical composition. J Bacteriol 1959; 78: 863-867.
37. Strominger JL, Park JT, Thompson RE: Composition of the cell wall of Staphylococcus aureus: its relation to the mechanism of action of penicillin. J Biol Chem 1959; 234: 3263-3268.
38. Pratt BC: Cell-wall deficiencies in L-forms of Staphylococcus aureus. J Gen Microbiol 1966; 42: 115-122.
39. Exterkate A, Veerkemp JH: Biochemical changes in Bifidobacterium bifidum var. pennsylvanicus after cell wall inhibition. IV. Galactolipid composition. Biochem Biophys Acta 1971; 231: 545-549.
40. Hagenmaier S, Stierhof YD, Henning U: A new periplasmic protein of Escherichia coli which is synthesized in spheroplasts but not in intact cells. J Bacteriol 1997; 179: 2073-2076.
41. Fodor M: Studies on the cell wall mucopeptide synthesis on staphylococcal L forms. Naturwissenschaften 1965; 52: 522-526.
42. Fleck J: Study of the glycopeptide of a stable L form of Proteus. II.-Lysozyme action. Ann Inst Pasteur (Paris) 1968; 115: 57-61 (in French).
43. Azuma I, Yamamura Y, Tahara T, Onoue K, Fukushi K: Isolation of tuberculin active peptides from cell wall fraction of human tubercle bacillus strain Aoyama B. Jpn J Microbiol 1969; 13: 220-222.
44. Oehring VH, Schumann D, Karl P, Knappe U, Gruhn I: Bacteriological findings in materials from patients with nonspecific odontogenic infections. Zahn Mund Kieferheilkd Zentralbl 1976; 64: 134-143 (in German).
45. Leutgeb W, Schwarz U: On the biosynthesis of murein. Zentralbl Bakteriol 1965; 198: 76-80 (in German).
46. Slabyj BM, Panos C: Teichoic acid of a stabilized L-form of Streptococcus pyogenes. J Bacteriol 1973; 114: 934-942.
47. Cohen M, Panos C: Membrane lipid composition of Streptococcus pyogenes and derived L-form. Biochemistry 1966; 5: 2385-2397.
48. Roth GS, Daneo-Moore L: Incorporation of radioactive macromolecular precursors into intact cells and osmotically stabilized "protoplasts" of Streptococcus faeculis. J Bacteriol 1971; 108: 980-985.
49. McFadden JJ, Kunze ZM, Portaels F, Labrousse V, Rastogi N: Epidemiological and genetic markers, virulence factors and intracellular growth of Mycobacterium avium in AIDS. Res Microbiol 1992; 143: 423-430.
50. Glennon PE, Head CEG, Roberts PR, Walker HA: Infective diseases of the heart. Cardiology. In: Medical Masterclass: Cardiology and Respiratory Medicine (Firth JD, Polkey MI, Roberts PR, eds). London: Royal College of Physicians of London, Blackwell Science, 2001; pp92-94.
51. Dressler FA, Roberts WC: Infective endocarditis in opiate addicts: analysis of 80 cases studied at necropsy. Am J Cardiol 1989; 63: 1240-1257.
52. Hampton JR, Harrison MJ: Sterile blood cultures in bacterial endocarditis. Q J Med 1967; 36: 167-174.
53. Kagan GY, Mikhailova VS: Isolation of L-forms of streptococci from blood of patients with rheumatism and endocarditis. J Hyg Epidemiol Microbiol Immunol 1963; 13: 327-343.
54. Louria DB: L forms, spheroplasts and aberrant forms in chronic sepsis. Adv Intern Med 1971; 17: 125-142.
55. Piepkorn MW, Reichenbach DD: Infective endocarditis associated with cell wall-deficient bacteria. Electron microscopic findings in four cases. Human Pathol 1978; 9: 163-173.
56. Slomska J: Bacteriological and serological studies in subacute bacterial endocarditis. Postepy Hyg Med Dosw 1958; 12: 311-363.
57. Wittler RG, Molizici WF, Kramer PE, Tuckett JD, Pritchard HN, Baker HJ: Isolation of a Corynebacterium and its transitional forms from a case of subacute bacterial endocarditis treated with antibiotics. J Gen Microbiol 1960; 23: 315-333.
58. Bouvet A, Ryter A, Frehel C, Acar JF: Nutritionally deficient streptococci: electron microscopic study of 14 strains isolated in bacterial endocarditis. Ann Micribiol (Paris) 1980; 131B: 101-120.
59. Pesonen E, Siitonen O: Acute myocardial infarction precipitated by infectious disease. Am Heart J 1981; 101: 512-513.
60. Valtonen VV: Infection as a risk factor for infarction and atherosclerosis. Ann Med 1991; 23: 539-543.
61. Saikku P, Lemonen M, Linnanmaki E, Mattila KJ, Nieminen MS, Valtonen VV: Association of immune complexes containing chlamydial lipopolysaccharide with coronary heart disease. In: Chlamydial Infections (Bowie WR, Caldwell HD, Jones RP, Mardh PE, Ridgway GL, Schacter J, Stamm WE, Ward ME, eds). Cambridge: Cambridge University Press, 1990, pp245-251.
62. Shor A, Kuo CC, Patton DL: Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82: 158-161.
63. Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ, et al: Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995; 92: 3397-3400.
64. Cook PJ, Lip GY: Infectious agents and atherosclerotic vascular disease. QJM 1996; 89: 727-735.
65. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B: Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet 1997; 350: 404-407.
66. Gupta S, Leatham EW, Carrington D, Mendall MA, Koski JC, Camm AJ: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardiol infarction. Circulation 1997; 96: 404-407.
67. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-1547.
68. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al: Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-1466.
69. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matezky S, et al: Effect of short-term treatment on recurrent ischaemic events in patients with acute coronary syndrome in the azithromycin in acute coronary syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361: 809-813.
70. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, et al: Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002; 105: 1555-1560.
71. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al: Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106: 1219-1223.
72. Flores AE, Ferrieri P: The type-specific polysaccharide and the R protein antigens of the L phase from a Group B, type III Streptococcus. Zentralbl Bakteriol Mikrobiol Hyg [A] 1985; 259: 165-178.
73. Gorelov AL, Levina GA, Prozorovskii SV: Detection of antigenemia in typhoid patients at different periods in the course of infection. Zh Mikrobiol Epidemiol Immunobiol 1989, 12: 33-36.
74. Kaplan MH: Immunologic relationship of group A streptococcal strains and human heart tissue. Possible significance for the pathogenesis of rheumatic fever. Am Heart J 1963. 65: 426-427.
75. Kaplan MH: Rheumatic fever, rheumatic heart disease, and the streptococcal connection: the role of streptococcal antigens cross-reactive with heart tissue. Rev Infect Dis 1979; 6: 986-988.
76. Rommelkamp CH, Stolzer BL: The latent period before the onset of acute rheumatic fever. Yale J Biol Med 1961; 34: 386-398.
77. Kowakita S, Iwamoto H, Yamadu J: Relationship between streptococcal infection and rheumatic fever. Jpn Circ J 1969; 33: 1499-1503.
78. Timakov VD, Kagan G: L forms of haemolytic streptococcus and their detection in the blood of patients with rheumatic fever and bacterial endocarditis. J Reumatisma 1962; 2: 3-8.
79. Gorina LG, Zheverzheeva IV, Chumachenko NV, Goncharova SA, Labinskaia AS: Detection of an antigen of the L-forms of a group A hemolytic streptococci in the sera of rheumatic patients following immune complex separation. Zh Mikrobiol Epidemiol Immunobiol 1981; 7: 42-46.
80. Scheff GJ, Marienfeld CJ, Hackett E: Blood cultures in rheumatic fever patients. J Infect Dis 1958; 103: 45-51.
81. Kagan G, Ya, Mikhailova VS: Biological properties of Streptococci reversed from L forms, isolated from patients suffering from rheumatism and endocarditis. Antibiotiki 1963; 9: 791-796.
82. Bhatia P, Polkey MI, White VLC: Sarcoidosis. In: Medical Masterclass: Cardiology and Respiratory Medicine (Polkey MI, Firth JD, eds). London: Royal College of Physicians of London, Blackwell Science, 2001; pp208-210.
83. Barksdale WL, Kim KS: Mycobacterium. Bacteriol Rev 1977; 41: 217-372.
84. Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA: Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease. J Clin Microbiol 1986; 24: 357-363.
85. Mankiewicz E: The relationship of sarcoidosis to anonymous bacteria. Acta Med Scand Suppl 1964; 425: 68-73.
86. Hanngren A, Biberfeldt G, Carlens E, Hectors E, Nilson BS, Ripe E: Is sarcoidosis due to an infectious interaction between virus and Mycobacterium? In: Proceedings of the 6th International Conference on Sarcoidosis (Iwai K, Hosoda Y, eds). Tokyo: University of Tokyo Press, 1974, pp8-11 (Abstract).
87. Steffen CM, Mattman LH: Identification of cell wall deficient mycobacteria with polyacrylamide gel electrophoresis. Michigan Academic Papers. Mich Acad Sci Arts Lett 1986; 17: 303-313.
88. Mangiapan G, Hance AJ: Mycobacteria and sarcoidosis: (in overview and summary of recent molecular biology data. Sarcoidosis 1995; 12: 20-37.
89. Almenoff PL, Johnson A, Lesser M, Mattman LH: Growth of acid fast L forms from the blood of patients with sarcoidosis. Thorax 1996; 51: 530-531.
90. Kon OM, du Bois RM: Mycobacteria and sarcoidosis. Thorax 1997; 52 (Suppl 3): S47-S51.
91. Brown ST, Brett I, Almenoff PL, Lesser M, Terrin M, Teirstein A: Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects. Chest 2003; 123: 413-417.
92. Mattman LH: Cell Wall Deficient Forms, 2nd edn. Boca Raton, FL: CRC Press, 1993; pp187-195.
93. Judge MS, Mattman LH, Domingue GL (eds): Cell Wall Deficient Bacteria, 2nd edn. Reading, MA: Addison-Wesley, 1982; pp257-298.
94. Greenstein RJ, Greenstein AJ: Is there clinical epidemiological and molecular evidence for two forms of Crohn's disease. Mol Med Today 1995; 1: 343-348.
95. Gilberts EC, Greenstein AJ, Katsel PL, Harpaz N, Greenstein RJ: Molecular evidence for two forms of Crohn disease. Proc Natl Acad Sci USA 1994; 91: 12721-12724.
96. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-769.
97. Holland SM: Cytokine therapy of mycobacterial infections. Adv Intern Med 2000; 45: 431-452.
98. Naser SA, Schwartz D, Shafran I: Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn's disease patients. Am J Gastroenterol 2000; 95: 1094-1095.
99. Richter E, Wessling J, Lugering N, Domschke W, Rusch-Gerdes S: Mycobacterium avium subsp. paratuberculosis infection in a patient with HIV, Germany. Emerg Infect Dis 2002; 8: 729-731.
100. Hermon-Taylor J, Barnes N, Clarke C, Finlayson C: Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. Br Med J 1998; 316: 449-453.
101. Gutknecht K: Dire warnings about Johne's disease. A wake up call to the dairy industry? Wisconsin Agriculturist 1997; December 8-15.
102. Wirostko E, Johnson L, Wirostko B: Crohn's disease: rifampicin treatment of the ocular and gut disease. Hepatogastroenterology 1987; 34: 90-93.
103. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C: Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-518.
104. Prantera C, Kohn A, Zannoni F, Spimpolo N, Bonfa M: Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study. J Clin Gastroenterol 1994; 19: 79-80.
105. Thomas GA, Swift GL, Green JT, Newcombe RG, Braniff-Mathews C, Rhodes J, et al: Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut 1998; 42: 497-500.
106. Greenstein RJ: Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis 2003; 3: 507-514.
107. Hampson SJ, Parker MC, Saverymuttu SH, Joseph AE, McFadden JJ, Hermon-Taylor J: Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther 1989; 3: 343-352.
108. Douglass A, Cann PA, Bramble MG: An open study of antimicrobial therapy in patients with unresponsive Crohn's disease. Gut 2000; 46 (Suppl 2): T41.
109. Moss AA, Carbone IV, Kressel HY: Radiologic and clinical assessment of broad spectrum antibiotic therapy in Crohn's disease. AJR Am J Roentgenol 1978; 131: 787-790.
110. Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J: Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 1997; 39: 393-400.
111. Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J: Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002; 34: 22-28.
112. Borody TJ, Leis S, Warren EF, Surace R: Treatment of severe Crohn's disease using antimycobacterial triple therapy - approaching a cure? Dig Liver Dis 2002; 34: 29-38.
113. Hill EO, Lewis S: L forms of bacteria isolated from surgical infections. Bacteriol Proc 1964; 48: 1964-1969.
114. Charache P, Kaslick D: Isolation of protoplasts in human infection. Clin Res 1965; 293-298.
115. Rosner R: Isolation of protoplasts of Staphylococcus aureus from a case of recurrent acute osteomyelitis. Tech Bull Regist Med Technol 1968; 38: 205-210.
116. Gordon SL, Greer RB, Craig CP: Recurrent osteomyelitis: report of four cases culturing L form variants of staphylococci. J Bone Joint Surg Am 1971; 53: 1150-1156.
117. Holmes KK, Gutman LT, Belding ME, Turck M: Recovery of Neisseria gonorrhoeae from 'sterile' synovial fluid in gonococcal arthritis. N Engl J Med 1971; 284: 318-320.
118. Palmer DW: Inadequate response to 'adequate' treatment of bacterial infection: L forms and 'bactericidal' antibiotic activity. J Infect Dis 1979; 139: 725-727.
119. Woo PC, Wong SS, Lum PN, Hui WT, Yuen KY: Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet 2001; 357: 675-679.
120. Sable CA, Donowitz GR: Infections in bone marrow transplant recipients. Clin Infect Dis 1994; 18: 273-281.
121. Yuen KY, Woo PCY, Hui CH, Luk WK, Chen FE, Lie AK, et al Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant 1998; 21: 1137-1143.
122. Russel NH: Haemopoietic stem-cell transplantation. In: Horizons in Medicine Number 11 (Pusey C, ed). London: Royal College of Physicians of London, 1999; pp351-358.
123. Kalmanson GM, Gaze LB: Role of protoplasts in pathogenesis of pyelonephritis. JAMA 1964; 190: 1107-1109.
124. Domingue GJ, Schlegel JU: Novel bacterial structures in human blood. II. Bacterial variants as etiologic agents in idiopathic hematuria. J Urol 1978; 120: 708-711.
125. Gutman LT, Turck M, Petersdorf RG, Wedgewood RJ: Significance of bacterial variants in urine of patients with chronic bacteriuria. J Clin Invest 1965; 44: 1945-1952.
126. Domingue GJ, Thomas R, Walters F, Serrano A, Heider PM: Cell wall deficient bacteria as a cause of idiopathic hematuria. J Urol 1993; 150: 483-485.
127. McFadyen IR, Eykyn SJ: Suprapubic aspiration of urine in pregnancy. Lancet 1968; 1: 1112-1114.
128. Fairley KF, Birch DF: Unconventional bacteria in urinary tract disease: Gardnerella vaginalis. Kidney Int 1983; 23: 862-865.
129. Alexander-Jackson E: A hitherto undemonstrated form of Mycobacterium tuberculosis. Ann N Y Acad Sci 1945; 46: 127-152.
130. Kagan GY, Koptelova EI, Pokrovsky BM: Isolation of pleuropneumonia-like organisms, L-forms and heteromorphous growth of bacteria from the cerebrospinal fluid of patients with septic meningitis. J Hyg Epidemiol Micrbiol Immunol 1965; 9: 310-317.
131. Calderon E, Akbuerne A, Gonzalez S, Winkler L: Cell wall deficient bacteria (L-forms) in meningitis. Rev Latinoam Microbiol 1971; 13: 95-100.
132. Timokov V: Bacterial L forms in pathology. In: Spheroplasts, Protoplasts and L Forms of Bacteria (Roux J, ed). Paris: INSERM, 1976; pp357-364.
133. Mattman LH: L forms isolated from infections. In: Microbial Protoplasts, Spheroplasts and L-forms (Guze IB, ed). Baltimore: Williams & Wilkins, 1968; pp472-483.
134. Kenny JF: Bacterial variants in central nervous system infections in infants and children. J Pediatr 1973; 83: 531-542.
135. Hodgson HJF. Whipple's disease. In: Oxford Textbook of Medicine, 2nd edn (Weatherall DJ, Ledingham JGG, Warrell DA, eds). Oxford University Press, 1987, pp636-637.
136. Relman DA, Schmidt TM, MacDermott RP, Falkow S: Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992; 327: 293-301.
137. Mitchell D, Parent K: Role of cell wall-deficient bacteria in diseases of the gastro-intestinal truct. In: Cell Wall-deficient Bacteria: Basic Principles and Clinical Significance (Domingue G, ed . Reading, MA: Addison Wesley Publishing Co., 1982: pp388.
138. Dobbins WO, Kawanishi H: Bacillary characteristics in Whipple's disease: an electron microscopic study. Gastroenterology 1981; 80: 1468-1475.
139. Wirostko E, Johnson L, Wirostko B: Sarcoidosis associated uveitis: parasitization of vitreous leucocytes by mollicute-like organisms. Acta Ophthalmol (Copenh) 1989; 67: 415-424.
140. Foulds WS: The uses and limitations of intraocular biopsy. Eye 1992: 6: 11-27.
141. Newsom SW: Staphylococcal persisters grown from empyema fluid on L-form medium. J Med Microbiol 1970; 3: 669-673.
142. Cantwell AR, Rowe L, Kelso DW: Nodular scleroderma and pleomorphic acid-fast bacteria. Arch Dermatol 1980; 116: 1283-1290.
143. Cantwell AR, Kelso DW, Jones JE: Histologic observations of coccoid forms suggestive of cell wall deficient bacteria in cutaneous and systemic lupus erythematosus. Int J Dermatol 1982; 21: 526-537.